Skip to main content
Apellis Pharmaceuticals, Inc. (APLS)
NASDAQ: APLS · Real-Time Price · USD
23.63
+1.44 (6.49%)
At close: Dec 5, 2025, 4:00 PM EST
23.23
-0.40 (-1.69%)
After-hours: Dec 5, 2025, 7:59 PM EST

Apellis Pharmaceuticals Revenue by Segment
Period Ending Sep 30, 2025Jun 30, 2025Mar 31, 2025Dec 31, 2024Sep 30, 2024Jun 30, 2024Mar 31, 2024Dec 31, 2023Sep 30, 2023Jun 30, 2023Mar 31, 2023Dec 31, 2022Sep 30, 2022Jun 30, 2022Mar 31, 2022Dec 31, 2021
Product
690.21M 689.03M 696.78M 709.95M 657.44M 580.05M 490.56M 366.28M
Product Growth
4.99% 18.79% 42.04% 93.83% 165.87% 249.90% 434.47% 462.71%
Collaboration License and Other
326.18M 65.62M 79.06M 71.41M 57.78M 48.74M 33.51M 30.31M
Collaboration License and Other Growth
464.53% 34.64% 135.91% 135.62% 125.73% 159.80% 137.61% 193.41%

Product Revenue by Segment
Period Ending Sep 30, 2025Jun 30, 2025Mar 31, 2025Dec 31, 2024Sep 30, 2024Jun 30, 2024Mar 31, 2024Dec 31, 2023Sep 30, 2023Jun 30, 2023Mar 31, 2023Dec 31, 2022Sep 30, 2022Jun 30, 2022Mar 31, 2022Dec 31, 2021
Syfovre
599.55M 600.59M 604.58M 611.85M 558.35M 481.67M 394.39M 275.28M - - - - - - - -
Syfovre Growth
7.38% 24.69% 53.30% 122.26% - - - - - - - - - - - -
Empaveli
90.69M 88.47M 92.22M 98.13M 99.13M 98.42M 96.21M 91.04M
Empaveli Growth
-8.52% -10.11% -4.15% 7.79% 14.81% 22.81% 30.91% 39.72%
Source: Business metrics provided by Main Street Data and sourced from official company press releases and documents.